Gout — NEJM
Jan 29, 2004. In discussing treatment options for gout Oct. 23 issue,1 Terkeltaub omitted the emerging role of fenofibrate. This fibric-acid derivative is used. Abstract. Objective. To assess the short‐term urate‐lowering effect of fenofibrate in men on long‐term allopurinol therapy for hyperuricaemia and gout. Methods. BACKGROUND To assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout. METHODS Fourteen male.
Effect of fenofibrate in combination with urate lowering agents in.
Fenofibrate, a derivative of fibric acid, is commonly used in the treatment of hyperlipidemia. Fenofibrate treatment has been shown to decrease serum uric acid. However, some patients still experience hyperuricaemia or gout, or both, despite allopurinol treatment. Fenofibrate is an established treatment for many common.
Effect of Fenofibrate in Combination with Urate. - NCBI - NIH
Serum uric acid was lowered by 23% after two months of fenofibrate treatment 6.93±2.16 vs. 5.22±1.16 mg/dL; p=0.016. Triglyceride levels were also reduced. Rheumatology Oxford. 2003 Feb;422321-5. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Feher MD1.